previously treated patients with advanced non-small cell lung cancer
Conditions
Interventions
Patients were treated at 3-week intervals with docetaxel on day 1 plus 80 mg/m2 oral S-1 from days 1 to 14
Sponsors
Clinical Research Support Center Kyushu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: a cytologically or histologically confirmed diagnosis of incurable previously treated non-small cell lung cancer no previous use of docetaxel or uracil plus tegafur(UFT) age between 20-75 years performance status of <=1 on the Eastern Cooperative Oncology Group scale an estimated life expectancy of >12 weeks adequate bone marrow function a measurable lesion according to the Response Evaluation Criteria in Solid Tumors guidelines version 1.0 provision of written informed consent
Exclusion criteria
Exclusion criteria: active infection, massive ascites or pleural effusion symptomatic brain metastasis uncontrollable diabetes mellitus severe comorbidity such as heart disease or renal disease, interstitial pneumonia, watery diarrhea, active concomitant malignancy pregnancy or lactation, or other medical problems severe enough to prevent compliance with the protocol Both of the following conditions were necessary an interval of at least 4 weeks after the end of final therapy and recovery from the previous treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine a recommended dose, ORR | — |
Countries
Japan
Contacts
Public ContactJunji Uchino
Kyoto Prefectural University of Medicine Department of Pulmonary Medicine
Outcome results
None listed